Capricor Therapeutics (CAPR) Cash & Equivalents (2010 - 2026)

Capricor Therapeutics' Cash & Equivalents history runs 17 years deep, the most recent figure standing at $105.4 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 266.12% year-over-year to $105.4 million; the TTM figure through Mar 2026 stood at $105.4 million (up 266.12% YoY), while the FY2025 annual figure was $287.8 million, up 2450.26% from the prior year.
• Cash & Equivalents was $105.4 million for Q1 2026 at Capricor Therapeutics, down from $287.8 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $287.8 million in Q4 2025 to a low of $6.2 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $41.1 million across 5 years, with a median of $14.7 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents slumped 81.82% in 2023, then jumped 2450.26% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $9.6 million in 2022, then jumped by 53.02% to $14.7 million in 2023, then slipped by 23.19% to $11.3 million in 2024, then surged by 2450.26% to $287.8 million in 2025, then plunged by 63.38% to $105.4 million in 2026.
• The last three Cash & Equivalents figures came in at $105.4 million (Q1 2026), $287.8 million (Q4 2025), and $19.5 million (Q3 2025), per Business Quant data.